Time patterns of recurrence and second primary tumors in a large cohort of patients treated for oral cavity cancer by Brands, M.T. et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/208433
 
 
 
Please be advised that this information was generated on 2019-12-04 and may be subject to
change.
5810  |    Cancer Medicine. 2019;8:5810–5819.wileyonlinelibrary.com/journal/cam4
Received: 2 October 2018 | Revised: 28 February 2019 | Accepted: 5 March 2019
DOI: 10.1002/cam4.2124  
O R I G I N A L  R E S E A R C H
Time patterns of recurrence and second primary tumors in a 
large cohort of patients treated for oral cavity cancer
Maria T. Brands1  |   Elisabeth A. J. Smeekens1 |   Robert P. Takes2 |    
Johannes H. A. M. Kaanders3 |   Andre L. M. Verbeek4 |   Matthias A. W. Merkx1 |    
Sandra M. E. Geurts4
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original 
work is properly cited.
© 2019 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
1Department of Oral and Maxillofacial 
Surgery, Radboud University Medical 
Centre, Nijmegen, The Netherlands
2Department of Ear Nose and Throat 
Surgery, Radboud University Medical 
Centre, Nijmegen, The Netherlands
3Department of Radiation 
Oncology, Radboud University Medical 
Centre, Nijmegen, The Netherlands
4Department for Health Evidence, Radboud 
University Medical Center, Nijmegen, The 
Netherlands
Correspondence
Maria T. Brands, Department of Oral 
and Maxillofacial Surgery, Radboud 
University Medical Centre, Nijmegen, The 
Netherlands.
Email: m.t.brands@gmail.com
Present Address
Maria T. Brands, Department of Oral and 
Maxillofacial Surgery, Queen Elizabeth 
Hospital, Queen Elizabeth University 
Hospital, Glasgow, United Kingdom
Elisabeth A. J. Smeekens, Department 
of Surgery, ETZ Hospital, Tilburg, The 
Netherlands
Sandra M. E. Geurts, Department of 
Medical Oncology, GROW‐School 
for Oncology and Developmental 
Biology, Maastricht University Medical 
Center, Maastricht, The Netherlands
Abstract
Introduction: Routine follow‐up after curative treatment of patients with oral squa-
mous cell carcinoma (OSCC) is common practice considering the high risk of second 
primaries and recurrences (ie second events). Current guidelines advocate a follow‐
up period of at least 5 years. The recommendations are not evidence‐based and ben-
efits are unclear. This is even more so for follow‐up after a second event. To facilitate 
the development of an evidence‐ and personalized follow‐up program for OSCC, we 
investigated the course of time until the second and subsequent events and studied 
the risk factors related to these events.
Materials and methods: We retrospectively studied 594 OSCC patients treated with 
curative intent at the Head and Neck Cancer Unit of the Radboud University Medical 
Centre from 2000 to 2012. Risk of recurrence was calculated addressing death from 
intercurrent diseases as competing event.
Results: The 1‐, 5‐ and 10‐year cumulative risks of a second event were 17% (95% 
CI:14%;20%), 30% (95% CI:26%;33%), and 37% (95% CI:32%;41%). Almost all lo-
coregional recurrences occurred in the first 2 years after treatment. The incidence of 
second primary tumors was relatively stable over the years. The time pattern of pres-
entation of third events was similar.
Discussion: Our findings support a follow‐up time of 2 years after curative treatment 
for OSCC. Based on the risk of recurrence there is no indication for a different fol-
low‐up protocol after first and second events. After 2 years, follow‐up should be 
tailored to the individual needs of patients for supportive care, and monitoring of late 
side‐effects of treatment.
K E Y W O R D S
head and neck cancer, oral cancer, postoperative surveillance, recurrence, routine follow‐up, second 
primary tumor
   | 5811BRANDS et Al.
1 |  INTRODUCTION
Oral squamous cell carcinoma (OSCC) continues to be an im-
portant burden on health care, with an increasing incidence 
and only moderately improving survival.1-4‐45% of OSCC 
patients will develop local‐ or regional recurrence (LRR), 
a second primary tumor (SPT) or distant metastasis (DM) 
(further called second events) after primary curative‐intent 
treatment.4,5 Current guideline‐recommendations advocate 
follow‐up after curative treatment for all patients of at least 
5 years.6 The main reason for follow‐up is the early detection 
of second events; other goals are functional rehabilitation and 
psychosocial support.
Follow‐up guidelines are not evidence‐ but consen-
sus‐based. Empirical studies on follow‐up after treatment 
for OSCC are scarce and usually combine the data of all 
HNC's, which have a different etiology, treatment, progno-
sis, and timing of second events.7-9 The available studies on 
OSCC are small and do not address the question whether 
specific patient groups are in need of more or less intensive 
follow‐up.10-13
The current “one‐size‐fits‐all” follow‐up programs can be 
criticized on several points.14,15 Firstly, it is questionable if 
such a program is beneficial to all patients as some may be at 
higher risk of a second event than others.16,17 The time frame 
of 5 years is debatable as most tumors seem to recur in the 
first few years.7,12 Furthermore, it has never been investigated 
whether patients should receive a different follow‐up sched-
ule after curative‐intent treatment of a second event.
It is of utmost importance to optimize and personalize 
OSCC follow‐up to avoid unnecessary testing and anxiety 
in patients, optimize the use of health care resources and 
minimize the time clinicians spend on ineffective follow‐up 
consultations. Therefore, this study investigates the time pat-
terns, risks, and treatment intent of second and subsequent 
events after curative‐intent treatment of OSCC.
2 |  MATERIALS AND METHODS
2.1 | Patients
Between 2000 and 2012, 756 patients were diagnosed with 
primary OSCC (ICD O codes C.00‐06 excluding C.01, 
C.05.1 en C.05.2) and treated at the Head and Neck Cancer 
Unit of the Radboud University Medical Centre. Of these 
patients, 57 were excluded from analysis for the following 
reasons: not a first primary OSCC (n = 23), a previous or 
synchronous tumor in other subsites of the head and neck 
area (n = 32) and other reasons (n = 2). Of the remaining 699 
patients, 594 (85%) were treated with curative intent and eli-
gible for analysis.
Patients were staged according to the seventh UICC TNM 
classification. Treatment intent and therapy choices were 
based on the Dutch national guideline. Decisions concerning 
therapy and treatment intent were taken after discussion in a 
multidisciplinary team meeting.15
Patients received follow‐up examinations every 2 and 
3 months during the first and second year posttreatment, 
respectively, every 4 months in the third year and every 
6 months during the fourth and fifth year. Survival was up-
dated in November 2014 using the municipal registration of 
deaths.
The difference between a LRR and a SPT was based on 
p53 mutation analysis. If unavailable, the modified Warren 
and Gates criteria as described by Re et al were used.18,19
2.2 | Statistical analysis
Overall survival (OS) from the date of last primary treatment 
was calculated with the Kaplan‐Meier method. Median fol-
low‐up time was determined by the inverse Kaplan‐Meier 
method (censored data as events).
Risk of recurrence was calculated using competing risk 
methods with death from intercurrent disease as competing 
event.20 Conditional risk of recurrence per follow‐up year 
was defined as the probability of experiencing a recurrence 
in that year (y), given that the patient had been recurrence‐
free up to the previous follow‐up year (x). Annual condi-
tional risk of event is calculated by dividing the cumulative 
risk of event‐free survival at “x + y” years after primary 
treatment by the cumulative risk at “x” years after treat-
ment.21 Risk estimates are given with 95% confidence in-
tervals (CI).
Independent prognostic factors were selected through 
forward stepwise regression with P < 0.10 as a cutoff. The 
Fine and Gray modified Cox proportional hazards model 
was used to determine prognostic factors for risk of recur-
rence. The hazard rate ratio's (sHR) for the final model in-
cluding the selected prognostic factors were presented. The 
observed 5‐year risks of recurrence for all combination of the 
selected prognostic variables were determined, categorized 
and presented in a flow chart. Logistic regression was per-
formed to identify prognostic factors for the probability of 
curative‐intent treatment. For the final model including the 
selected factors, the odds ratios (OR) were presented, and the 
observed proportion of second events treated with curative 
intent categorized. The potential prognostic factors studied 
are presented in the (Table S1).
3 |  RESULTS
3.1 | First event
The patient, tumor, and treatment characteristic of 594 pa-
tients treated with curative intent for primary OSCC (first 
event) are displayed in Table 1.
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T A B L E  1  Patient, tumor and treatment characteristics, and survival and recurrence rates of patients treated for primary (N = 594) and 
recurrent (N = 106) OSCC with curative intent
First event (N = 594) Second event (N = 106)
No % No %
Overall 594 106
Patient characteristics
 Gender Male 359 60% 62 58%
Female 235 40% 44 42%
 Age at diagnosis <40 years 24 4% 6 6%
40‐60 years 237 40% 32 30%
≥60 years 333 56% 68 64%
 ASA score at primary diagnosis I 145 24% 29 27%
II 323 54% 59 56%
III 96 16% 13 12%
IV 2 1% – –
Unknown 28 5% 5 5%
 Malignancies in the past (primary diagnosis) Yes 35 6% 2 2%
No 559 94% 104 98%
 Oral premalignancies in the past (primary diagnosis) Yes 27 4% 12 11%
No 564 95% 94 89%
Unknown 3 1% – –
 Karnofsky Performance Score at primary diagnosis <60 3 1% – –
60 13 2% – –
70 18 3% 2 2%
80 32 6% 7 7%
90 79 13% 12 11%
100 55 9% 16 15%
Unknown 394 66% 69 65%
 Smoking and alcohol at primary diagnosis Never smoker, none‐moder-
ate alcohol use
96 16% 25 24%
Never smoker, problematic 
alcohol use
3 1% 0 –
(ex) smoker, none‐moderate 
alcohol use
217 36% 38 36%
(ex) smoker, problematic 
alcohol use
206 35% 31 29%
Unknown 72 12% 12 11%
Tumor characteristics
 Tumor stage 1 222 37% 36 34%
2 214 36% 10 9%
3 45 8% 5 5%
4 (a+b) 113 19% 5 5%
Unknown – – 50 47%
 Nodal stage 0 368 62% 55 52%
1 68 12% 17 16%
2 127 21% 10 9%
Unknown 31 5% 24 23%
(Continues)
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3.1.1 | Risk of a second event
The 1‐, 5‐, and 10‐year cumulative risks of a second event 
(ie recurrence, new primary tumor or DM) were 17% 
(CI:14%;20%), 30% (CI:26%;33%) and 37% (CI:32%;41%). 
The majority of LRR occurred within the first year after 
treatment, and all the DMs within 3 years. The incidence 
rate of SPTs was stable over the entire follow‐up period 
(Figure 1A).
Annual conditional risk of a second event was highest in 
the first year of follow‐up. that is, 17% and decreasing in the 
following years (Figure 1C). Annual conditional risks of a 
second event were higher for the nonsurgically treated group 
compared with the surgically treated group (Figure S1).
Surgical primary treatment was a statistically sig-
nificant prognostic factor for risk of a second event (P‐
value Gray test: <0.01). The 5‐year cumulative risk was 
28% (CI:25%;32%) after surgical treatment and 50% 
(CI:31%;67%) after nonsurgical treatment. In patients 
treated surgically, vasoinvasive growth, cervical lymph 
node dissection, buccal mucosa, and extranodal growth 
were important independent prognostic factors for risk of 
second event (Table 2). Based on these factors, a flowchart 
was built with corresponding 5‐year cumulative risks of 
a second event (Figure 2). Nine risk groups, with an ob-
served 5‐year risk of second event varying between <10% 
for patients who received surgical treatment and had a pre-
vious malignancy and 50%, for patients without surgical 
First event (N = 594) Second event (N = 106)
No % No %
 Stage 1 177 30% 33 31%
2 129 22% 8 8%
3 68 11% 9 8%
4 189 32% 6 6%
Unknown 31 5% 50 47%
 Location Tongue 216 36% 20 19%
Buccal mucosa 48 8% 9 8%
Floor of the mouth 208 35% 16 15%
Retromolar trigone 52 9% 4 4%
Alveolar process 66 11% 14 13%
Other 4 1% 43 41%
Treatment characteristics
 Therapy Surgery only 260 44% 53 50%
Radiotherapy only 11 2% 8 8%
Surgery and radiotherapy 276 46% 28 26%
Surgery and chemoradiation 27 5% 8 8%
Chemoradiation 20 3% 6 5%
Chemotherapy only – 2 2%
Surgery and chemotherapy – 1 1%
 Surgery Yes 563 95% 89 84%
No 31 5% 17 16%
 Optimal treatment as advised by the multi discipli-
nary team meeting 
Yes 509 86% 82 77%
No 78 13% 22 21%
Unknown 7 1% 2 2%
 Follow‐up characteristics
 Follow‐up time Median (range) years 7.8 (0.1‐14.5) 6.0 (0.1‐13.0)
 5‐year overall survival % (95% CI) 65% (61%;69%) 64% (52%;74%)
 5‐year CIF recurrence % (95% CI) recurrence 30% (26%;33%) 36% (26%;46%)
 5‐year CIF competing event % (95% CI) intercurrent 
death
17% (14%;20%) 21% (13%;31%)
T A B L E  1  (Continued)
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treatment were identified. The group size of the nonsurgi-
cally treated group did not permit further risk stratification, 
but were considered as separate risk group.
3.1.2 | Treatment intent
The proportion of the 193 second events that could be 
treated with curative intent increased with follow‐up time 
from 32% (CI:20%;45%) for early recurrences (0‐6 months 
after treatment) to 71% (CI:57%;69%) for patients who had 
a second event 24‐60 months after treatment. The annual 
conditional risk of a second event that could not be treated 
curatively was highest in the first year after treatment 
(Figure 1E). The proportion of patients with a LRR that 
could be treated curatively decreased, while the proportion 
of patients with a SPT that could be treated curatively was 
stable over time.
Patients having their recurrence detected after primary 
surgical treatment had a higher chance of curative treatment 
of the second event when compared with recurrences detected 
after non‐surgical treatment: 58% (CI:50%;65%) vs 25% 
(CI:10%;50%). In patients treated surgically, postoperative 
F I G U R E  1  Cumulative risk of second event (A,B), annual conditional risk of second event by event type (C,D) and treatment intent (E,F). 
(A) Cumulative risk of a second event, by event type. (B) Cumulative risk of a third event, by event type. (C) Annual conditional risk of a second 
event, by event type. (D) Annual conditional risk of a third event, by event type. (E) Annual conditional risk of a second event, by treatment intent. 
(F) Annual conditional risk of a third event, by treatment intent
A B
C
E F
D
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radiotherapy for the first event, tumor size, nodal status, 
ASA‐score, and invasion depth were important independent 
prognostic factors for curative‐intent treatment of a second 
event (Table 3). Based on the number of risk factors, the 
chance of curative intent treatment varied between 0% (four 
risk factors) and 96% (no risk factors) (Table 4).
3.2 | Second event
The characteristics of the 106 patients curatively treated for a 
second event are summarized in Table 1. The 5‐year OS rate 
after completion of the treatment of the second event was 
49% (CI:38%;59%).
3.2.1 | Risk of a third event
The 1‐, 5‐, and 10‐year cumulative risks of a third event 
were 23% (CI:16;32%), 37% (CI:27%;47%), and 45% 
(CI:32%;57%). Almost all local and/or regional recurrences 
occurred within 2 years after treatment (Figure 1B). The risk 
of a new primary tumor as third event was constant over time.
The annual conditional risk of a third event was 24% in 
the first year after treatment, 7% in the second year and de-
creased to 4% in the fifth year after treatment (Figure 1D).
The risk for a third event did not significantly differ be-
tween patients treated with (n = 88) and without (n = 17) 
surgery for their second event (P‐value Gray test: 0.42). The 
number of third events was too small (n = 38) for a reliable 
search for independent prognostic factors. However, univari-
able analyses for prognostic factors for the risk of a third 
event showed similar trends when compared with univariable 
analyses for the risk of a second event (Table S1).
3.2.2 | Treatment intent
Of the 38 third events, 16 (42%) could be treated with cura-
tive intent (Figure 1F). SPTs were more often treated with 
curative intent (58%) than LRRs (39%). None of the three 
DMs were treated with curative intent. Patient numbers were 
too small to draw conclusions about the trends in time or to 
reliably compare prognostic factors for treatment intent for 
second vs third events. Patient‐ and tumor‐related factors for 
second and third events and their relationship with treatment 
intent are presented in the appendix (Table S2).
4 |  DISCUSSION
This study is the first comprehensive analysis of patterns of 
occurrence of new disease that focuses specifically on OSCC. 
First and second events which include both recurrences and 
SPTs in a large cohort with a long follow‐up time are de-
scribed. The cumulative risk of recurrence for both surgically 
and nonsurgically treated patients was highest in the first year 
after treatment. Almost all LRRs occurred in the first 2 years 
after treatment. The incidence of SPTs was stable over the 
years. The time patterns of presentation of third events did 
not differ from that of second events. Our results are clinically 
highly relevant, because these patterns are not adequately re-
flected in the current guidelines for routine follow‐up after 
OSCC treatment which advocate 5 year or lifelong follow‐up 
after the treatment for OSCC.15,22 Determining the optimal 
follow‐up schedule is very important from a patient's per-
spective, because unnecessary follow‐up will create unneces-
sary anxiety and false expectations.
Our results are consistent with the results from other 
authors who reported that 86%‐94% of new disease after 
curatively treated OSCC occurred within 2 years.11,12,23,24 
Consistent with Vaamonde et al we confirm that the risk for a 
SPT is stable over time.25
Arguments for lifelong follow‐up are based on the as-
sumption that early, asymptomatic, detection of new primary 
tumors leads to improved survival. The literature, which 
comprises all HNCs rather than the oral cavity alone, remains 
equivocal on this subject.26 Site‐specific studies on laryngeal 
carcinomas and early‐stage OSCC did not show survival ben-
efits.27 The proportion of patients treated with curative in-
tent in our study did not differ between SPTs detected within 
5 years (ie during the follow‐up period) and those detected 
after 5 years, suggesting that it is safe to shorten the fol-
low‐up period. When shortening the follow‐up program, it 
is important to educate patients about the symptoms of new 
disease and provide them easy access to the clinic in case of 
symptoms.28
If follow‐up is proven to be beneficial to patients, cus-
tomization of follow‐up schedules based on risk of recur-
rence can be beneficial. Using 6 independent prognostic 
factors, namely surgical treatment, previous malignancy, 
presence of vasoinvasive growth, neck dissection, localiza-
tion of the tumor and the presence of extranodal growth, 
we were able to identify patient groups with 5‐year risks of 
a second event varying between <10% and 50%. The prog-
nostic value of these factors has been confirmed by several 
other authors.29,30 In our patient group the risk of recur-
rence between the different locations differed significantly 
T A B L E  2  Independent prognostic factors for the risk of 
recurrence after curative‐intent surgical treatment for primary OSCC: 
results from the forward selection procedure
Prognostic factor sHR (95% CI)
Vasoinvasive growth (yes vs no) 1.6 (1.1; 2.2)
Cervical node dissection (yes vs no) 0.6 (0.4; 0.8)
Buccal mucosa (vs all other locations) 2.1 (1.3; 3.3)
Extranodal growth (yes vs no) 1.6 (1.0; 2.5)
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(P < 0.01). The literature concerning the effect of location 
on the risk of recurrence is not unequivocal, with some 
authors reporting a significant effect on the risk of recur-
rence31,32 and others not.33,34 This reflects the complex 
multifactorial nature of oral cancer, which goes beyond 
purely anatomical factors.
Of interest is also that patients with a previous malignancy 
have a statistically significant lower risk of second events. This 
F I G U R E  2  Flow chart for the observed 5‐year cumulative risk of a second event after curative‐intent treatment for OSCC
Vasoinvasive 
growth 
5 y CR
30%
5 y CR
20%
No Yes
Vasoinvasive 
growth 
5 y CR
50%
5 y CR
30%
No
No Yes
Extranodal 
growth 
Neck 
dissection 
Surgical 
treatment
5 y CR
50 %
Tumor of the 
buccal musosa
Previous 
malignancies
5 y CR
<10%
5 y CR
50%
Yes
Yes
No
No
Yes
No
Yes
No
Vasoinvasive 
growth 
5 y CR
50%
5 y CR
30%
No Yes
Yes
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is likely to be caused by the fact that they have a higher risk of 
intercurrent death from other causes (data not shown). Another 
important prognostic factor for a second event was if the pa-
tient underwent an elective neck dissection for the treatment 
of their first primary tumor. This can partially be explained by 
the fact that patients with a clinically negative neck, a small 
tumor and an invasion depth <4 mm did not undergo an elec-
tive neck dissection. Montero et al built a nomogram predicting 
the probability of LRR‐free survival comprising nodal status, 
the subsites, bone invasion and primary tumor size.35 These pa-
rameters largely overlap ours. If routine follow‐up is considered 
effective, the nomograms for the risk of a second event might 
aid the development of a personalized follow‐up program, but 
should undergo further detailed evaluation and validation.
Another way to personalize follow‐up is by considering 
the chance of curative intent treatment of a second event. This 
strategy has been advocated by Kanatas et al, who suggested 
that patients with early disease who were treated with a sin-
gle modality, might benefit from earlier discharge.36 Patients 
who develop DM will have no chance to be cured. The likeli-
hood of curative intent treatment of the second event could be 
predicted using 5 factors, that is previous radiotherapy, nodal 
status of the first primary tumor, tumor size, invasion depth, 
and ASA‐score resulting in observed probabilities ranging 
between 0% and 96%. The factors associated with a treatment 
with curative intent are all related to the possibilities a patient 
has left to receive therapy. Many patients will have under-
gone treatment for the neck consisting of neck dissection and/
or (chemo)radiotherapy.4 Several authors confirmed that pa-
tients with previous neck dissections had a markedly smaller 
chance of successful salvage surgery.24,37,38 Likewise, in most 
patients who had previous radiotherapy another course of ra-
diotherapy will not be possible.39
Other authors mentioned performance status, ASA‐score 
and previous quality of life as important factors for a successful 
salvage.9 Our results confirm that time to recurrence yields im-
portant prognostic information for the success of salvage.24,40,41 
This is the first attempt to determine subgroups of patients for 
whom curative treatment of second events may be available. 
Patients who are unlikely to be treated curatively for their next 
event might benefit from a follow‐up program that focuses more 
on quality of life than on the early detection of new disease.
A limitation of this study is that changes in patient‐related 
factors such as smoking, alcohol use and ASA‐score could 
not be taken into account as these data were only available at 
the time of the first diagnosis.42 As the Karnofsky score was 
only available in 44% of the patients, we could not include 
this parameter in our prediction models.
Strengths of this study are the large, site‐specific patient 
cohort that was followed by a strict protocol with very high 
compliance rates and the description both first and second 
events. By the use of competing‐risk analysis, a more accu-
rate estimation of absolute risks is given than the Kaplan‐
Meier method which usually overestimates the cumulative 
risk of events when competing risks, like mortality, occur.
Our study shows that a 2‐year follow‐up period is suffi-
cient for the detection of LRRs. Longer follow‐up may be 
indicated on an individual basis for treatment‐related mor-
bidities and dental rehabilitation.43,44 We therefore advocate 
a personalized follow‐up schedule with a “core follow‐up” 
for 2 years after which frequency, type of clinician and du-
ration are tailored to the patient's needs. In order to timely 
diagnose new disease after discharge, patients should be ed-
ucated to recognize symptoms of new disease.36
Our findings support a follow‐up time of 2 years after cu-
rative‐intent treatment for OSCC. Longer follow‐up may be 
needed for some individual patients due to treatment‐related 
morbidities and psychological needs. Based on the patterns 
of occurrence of third events, a separate follow‐up protocol 
after curative treatment of a second event is not needed. The 
2 prediction models developed in this study might, after val-
idation, be a good starting point when personalizing OSCC 
follow‐up. In order to further optimize the guidelines for 
follow‐up and determine the optimal duration of follow‐up 
future research should focus on elucidating the benefits and 
risks of risk‐stratified follow‐up and its influence on survival 
or quality of life.
T A B L E  3  Independent prognostic factors for the treatment intent 
of second events after curative‐intent surgical treatment for primary 
OSCC: results from the forward selection procedure
Prognostic factor OR (95% CI)
Radiotherapy (yes vs no) 0.1 (0.0; 0.4)
Nodal stage 2 (vs stage 0 or 1) 0.2 (0.1; 0.5)
Tumor stage 4 (vs stage 1‐3) 0.1 (0.0; 0.5)
ASA III or IV (vs ASA I or II) 0.1 (0.0; 0.4)
Invasion dept ≥4 mm (vs <4 mm) 0.3 (0.1;1.3)
T A B L E  4  The observed proportion of patients with their second 
event treated with curative intent related to the number of risk factors, 
relating to the first primary OSCC (radiotherapy, pN2, pT4, ASA3/4, 
invasion depth >4 mm)
Number of risk 
factors
Number of 
patients
Observed % 
curative intent (95% CI)
0 27 96% 81%‐100%
1 30 97% 83%‐100%
2 39 62% 45%‐77%
3 38 26% 13%‐43%
4 12 0% 0%‐26%a 
Missing 
information on 
one or more 
risk factors
31 42% 25%‐61%
aOne‐sided, 97.5% confidence interval. 
5818 |   BRANDS et Al.
CONFLICT OF INTEREST
The authors declare no conflict of interest.
ORCID
Maria T. Brands  https://orcid.org/0000-0001-5807-1619 
REFERENCES
 1. Karim‐Kos HE, de Vries E, Soerjomataram I, Lemmens V, Siesling 
S, Coebergh JW. Recent trends of cancer in Europe: a combined 
approach of incidence, survival and mortality for 17 cancer sites 
since the 1990s. Eur J Cancer. 2008;44:1345‐1389.
 2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer 
J Clin. 2016;66:7‐30.
 3. van Dijk BA, Brands MT, Geurts SM, Merkx MA, Roodenburg 
JL. Trends in oral cavity cancer incidence, mortality, survival and 
treatment in the Netherlands. Int J Cancer. 2016;139:574‐583.
 4. Rogers SN, Brown JS, Woolgar JA, et al. Survival following pri-
mary surgery for oral cancer. Oral Oncol. 2009;45:201‐211.
 5. Mucke T, Wagenpfeil S, Kesting MR, Holzle F, Wolff KD. 
Recurrence interval affects survival after local relapse of oral can-
cer. Oral Oncol. 2009;45:687‐691.
 6. Brands MT, Brennan PA, Verbeek ALM, Merkx MAW, Geurts 
SME. Follow‐up after curative treatment for oral squamous cell 
carcinoma. A critical appraisal of the guidelines and a review of 
the literature. Eur J Surg Oncol. 2018;44:559‐565.
 7. Boysen M, Lovdal O, Tausjo J, Winther F. The value of follow‐up 
in patients treated for squamous cell carcinoma of the head and 
neck. Eur J Cancer. 1992;28:426‐430.
 8. Kothari P, Trinidade A, Hewitt RJD, Singh A, O'Flynn P. The fol-
low‐up of patients with head and neck cancer: an analysis of 1,039 
patients. Eur Arch Otorhinolaryngol. 2011;268:1191‐1200.
 9. Ho AS, Kraus DH, Ganly I, Lee NY, Shah JP, Morris LG. Decision 
making in the management of recurrent head and neck cancer. 
Head Neck. 2014;36:144‐151.
 10. Liu CH, Chen HJ, Wang PC, Chen HS, Chang YL. Patterns 
of recurrence and second primary tumors in oral squamous cell 
carcinoma treated with surgery alone. Kaohsiung J Med Sci. 
2013;29:554‐559.
 11. Merkx MA, van Gulick JJ, Marres HA, et  al. Effectiveness of 
routine follow‐up of patients treated for T1‐2N0 oral squamous 
cell carcinomas of the floor of mouth and tongue. Head Neck. 
2006;28:1‐7.
 12. Sasaki M, Aoki T, Karakida K, et  al. Postoperative follow‐up 
strategy in patients with oral squamous cell carcinoma. J Oral 
Maxillofac Surg. 2011;69:e105‐e111.
 13. Taslim SJ, Leemans CR, van der Waal I, Karagozoglu KH. Follow‐
up of oral cancer patients: three uneventful years may be enough. 
Oral Surg Oral Med Oral Pathol Oral Radiol. 2016;122:434‐439.
 14. Crawford B, Greenberg DD. Patient Surveillance after Cancer 
Treatment. New York: Springer; 2013.
 15. Nederlandse Werkgroep Hoofd-halstumoren. Richtlijn Mondholte‐ 
en Orofarynxcarcinoom Alphen aan den Rijn: Van Zuiden commu-
nications B.V. 2004.
 16. Flynn CJ, Khaouam N, Gardner S, et al. The value of periodic fol-
low‐up in the detection of recurrences after radical treatment in 
locally advanced head and neck cancer. Clin Oncol (R Coll Radiol). 
2010;22:868‐873.
 17. Cooney TR, Poulsen MG. Is routine follow‐up useful after com-
bined‐modality therapy for advanced head and neck cancer? Arch 
Otolaryngol Head Neck Surg. 1999;125:379‐382.
 18. Warren S, Gates L. Multiple malignant tumors, a survey of the lit-
erature and statistical study. Am J Cancer. 1932;16:1358‐1414.
 19. Curtis R, Ries L. New Malignancies among Cancer Survivors: 
SEER Cancer Registries 1973–2000. Bethesda: National Cancer 
Institute; 2006:9‐14.
 20. Coviello V, Boggess M. Cumulative incidence estimation in the 
presence of competing risks. Stata J. 2004;4:103‐112.
 21. Skuladottir H, Olsen JH. Conditional survival of patients with the 
four major histologic subgroups of lung cancer in Denmark. J Clin 
Oncol. 2003;21:3035‐3040.
 22. NCCN. NCCN Clinical Practice Guidelines in Oncology. Version 
2.2016 — October 11, 2016; 2016.
 23. Kissun D, Magennis P, Lowe D, Brown JS, Vaughan ED, Rogers 
SN. Timing and presentation of recurrent oral and oropharyngeal 
squamous cell carcinoma and awareness in the outpatient clinic. Br 
J Oral Maxillofac Surg. 2006;44:371‐376.
 24. Kowalski LP. Results of salvage treatment of the neck in pa-
tients with oral cancer. Arch Otolaryngol Head Neck Surg. 
2002;128:58‐62.
 25. Vaamonde P, Martin C, del Rio M, LaBella T. Second primary ma-
lignancies in patients with cancer of the head and neck. Otolaryngol 
Head Neck Surg. 2003;129:65‐70.
 26. Liu G, Dierks EJ, Bell RB, Bui TG, Potter BE. Post‐therapeutic 
surveillance schedule for oral cancer: is there agreement? Oral 
Maxillofac Surg. 2012;16:327‐340.
 27. Ritoe SC, Krabbe PF, Kaanders JH, van den Hoogen FJ, Verbeek 
AL, Marres HA. Value of routine follow‐up for patients cured of 
laryngeal carcinoma. Cancer. 2004;101:1382‐1389.
 28. De Zoysa N, Lee A, Joshi A, et  al. Developing a follow‐up sur-
veillance protocol in head and neck oncological surgery: enhanced 
‘traffic light’ surveillance ‐ a prospective feasibility study. Clin 
Otolaryngol. 2017;42:446‐450.
 29. Jung YH, Song CM, Park JH, et  al. Efficacy of current regular 
follow‐up policy after treatment for head and neck cancer: need 
for individualized and obligatory follow‐up strategy. Head Neck. 
2014;36:715‐721.
 30. Agrawal A, Hammond TH, Young GS, Avon AL, Ozer E, Schuller 
DE. Factors affecting long‐term survival in patients with recurrent 
head and neck cancer may help define the role of post‐treatment 
surveillance. Laryngoscope. 2009;119:2135‐2140.
 31. Fan KH, Wang HM, Kang CJ, et al. Treatment results of postoper-
ative radiotherapy on squamous cell carcinoma of the oral cavity: 
coexistence of multiple minor risk factors results in higher recur-
rence rates. Int J Radiat Oncol Biol Phys. 2010;77:1024‐1029.
 32. Brandwein‐Gensler M, Teixeira MS, Lewis CM, et al. Oral squa-
mous cell carcinoma: histologic risk assessment, but not margin 
status, is strongly predictive of local disease‐free and overall sur-
vival. Am J Surg Pathol. 2005;29:167‐178.
 33. Huang TY, Hsu LP, Wen YH, et al. Predictors of locoregional re-
currence in early stage oral cavity cancer with free surgical mar-
gins. Oral Oncol. 2010;46:49‐55.
 34. Ghantous Y, Bahouth Z, Abu El‐Naaj I. Clinical and genetic sig-
natures of local recurrence in oral squamous cell carcinoma. Arch 
Oral Biol. 2018;95:141‐148.
   | 5819BRANDS et Al.
 35. Montero PH, Yu C, Palmer FL, et al. Nomograms for preoperative 
prediction of prognosis in patients with oral cavity squamous cell 
carcinoma. Cancer. 2014;120:214‐221.
 36. Kanatas A, Bala N, Lowe D, Rogers SN. Outpatient follow‐up ap-
pointments for patients having curative treatment for cancer of the 
head and neck: are the current arrangements in need of change? Br 
J Oral Maxillofac Surg. 2014;52:681‐687.
 37. Wong LY, Wei WI, Lam LK, Yuen AP. Salvage of recurrent head 
and neck squamous cell carcinoma after primary curative surgery. 
Head Neck. 2003;25:953‐959.
 38. Lim JY, Lim YC, Kim SH, Byeon HK, Choi EC. Factors predictive 
of successful outcome following salvage treatment of isolated neck 
recurrences. Otolaryngol Head Neck Surg. 2010;142:832‐837.
 39. Argiris A, Li Y, Forastiere A. Prognostic factors and long‐term sur-
vivorship in patients with recurrent or metastatic carcinoma of the 
head and neck. Cancer. 2004;101:2222‐2229.
 40. Goodwin WJ Jr. Salvage surgery for patients with recurrent squa-
mous cell carcinoma of the upper aerodigestive tract: when do the 
ends justify the means? Laryngoscope. 2000;110:1‐18.
 41. Kernohan MD, Clark JR, Gao K, Ebrahimi A, Milross CG. Predicting 
the prognosis of oral squamous cell carcinoma after first recur-
rence. Arch Otolaryngol Head Neck Surg. 2010;136:1235‐1239.
 42. Bosetti C, Gallus S, Peto R, et al. Tobacco smoking, smoking ces-
sation, and cumulative risk of upper aerodigestive tract cancers. Am 
J Epidemiol. 2008;167:468‐473.
 43. Pagh A, Grau C, Overgaard J. A longitudinal study of follow‐up 
activities after curative treatment for head and neck cancer. Acta 
Oncol. 2015;54:813‐819.
 44. Wetzels JW, Koole R, Meijer GJ, de Haan AF, Merkx MA, 
Speksnijder CM. Functional benefits of implants placed during 
ablative surgery: a 5‐year prospective study on the prosthodontic 
rehabilitation of 56 edentulous oral cancer patients. Head Neck. 
2016;38(Suppl 1):E2103‐E2111.
SUPPORTING INFORMATION
Additional supporting information may be found online in 
the Supporting Information section at the end of the article.    
How to cite this article: Brands MT, Smeekens EAJ, 
Takes RP, et al. Time patterns of recurrence and 
second primary tumors in a large cohort of patients 
treated for oral cavity cancer. Cancer Med. 
2019;8:5810–5819. https://doi.org/10.1002/cam4.2124
